AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

British pharmaceutical giant AstraZeneca on Friday said that it will invest $2.5 billion in a research and development center in Chinese capital Beijing. The new hub is expected to take ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its ...

AstraZeneca AZN-0.91%decrease; red down pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...